Related Experiment Video
Updated: Aug 13, 2026

Isolation of Viral Replication Compartment-enriched Sub-nuclear Fractions from Adenovirus-infected Normal Human Cells
Published on: November 12, 2015
Activating Ras mutations fail to ensure efficient replication of adenovirus mutants lacking VA-RNA
Michael Schümann1, Matthias Dobbelstein
1Institut für Virologie, Klinikum der Philipps-Universität Marburg, Marburg, Germany.
Abstract:
Adenoviruses lacking their PKR-antagonizing VA RNAs replicate poorly in primary cells. It has been suggested that these virus recombinants still replicate efficiently in tumor cells with Ras mutations and might therefore be useful in tumor therapy. The ability of interferon-sensitive viruses to grow in Ras-mutant tumor cells is generally ascribed to a postulated inhibitory effect of mutant Ras on PKR. We have constructed a set of isogenic adenoviruses that lack either or both VA RNA species, and tested virus replication in a variety of cell species with different Ras status. In tendency, VA-less viruses replicated with higher efficiency in Ras-mutant cells, as compared to cell lines without Ras mutation. However, several exceptions to this rule were observed, arguing against a direct inhibition of PKR by mutant Ras. Phosphorylation of the PKR-substrate eIF2alpha was observed regardless of the Ras mutational status, upon infection with VA-less adenoviruses in the presence of interferon, but also upon addition of the PKR activator polyIC to cells. When comparing two isogenic cell lines that differ solely with regard to the presence or absence of mutant Ras, no difference was observed concerning the replication of VA-less adenoviruses or the phosphorylation of eIF2alpha. We conclude that mutant Ras does not directly affect eIF2alpha phosphorylation or the replication of interferon-sensitive adenoviruses. These results strongly suggest that the Ras mutational status is insufficient to predict the oncolytic effect of interferon-sensitive viruses. We propose that Ras mutations predispose tumor cells to undergo secondary changes that sometimes enable the replication of interferon-sensitive viruses.
Insights
Adenoviruses lacking VA RNAs replicate poorly in normal cells but may infect tumor cells. Ras mutations do not directly enhance replication of these viruses, suggesting other factors are involved in tumor therapy potential.
Area of Science:
- Virology
- Oncology
- Molecular Biology
Background:
- Adenoviruses lacking VA RNAs exhibit impaired replication in primary cells.
- These viruses are hypothesized to replicate efficiently in Ras-mutant tumor cells, indicating potential for cancer therapy.
Purpose of the Study:
- To investigate the role of Ras mutations in the replication of adenoviruses lacking VA RNAs.
- To determine if Ras mutations directly influence PKR activity and viral replication in tumor cells.
Main Methods:
- Constructed isogenic adenoviruses lacking VA RNA species.
- Assessed viral replication in various cell lines with different Ras mutational statuses.
- Analyzed phosphorylation of PKR substrate eIF2alpha.
Main Results:
- VA-less adenoviruses showed a tendency for higher replication in Ras-mutant cells, but with notable exceptions.
- Mutant Ras did not directly inhibit PKR-mediated eIF2alpha phosphorylation.
- Isogenic cell lines differing only in Ras status showed no difference in viral replication or eIF2alpha phosphorylation.
Conclusions:
- Mutant Ras does not directly impact eIF2alpha phosphorylation or the replication of interferon-sensitive adenoviruses.
- Ras mutational status is insufficient to predict the oncolytic efficacy of these viruses.
- Ras mutations may predispose tumor cells to secondary alterations that facilitate virus replication.
Related Concept Videos
The Ras Gene
Ras is a superfamily...
Viral Mutations
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Inhibitors Of Virion Release

